CheloniaSwiss Profile Banner
Chelonia Applied Science Profile
Chelonia Applied Science

@CheloniaSwiss

Followers
165
Following
807
Statuses
1K

Engineering Your Innovation DNA—Transforming Scale into Competitive Strength

Allschwil
Joined December 2019
Don't wanna be here? Send us removal request.
@CheloniaSwiss
Chelonia Applied Science
10 hours
Ready to bridge lab discoveries with market success? Check out Chelonia’s new article on accelerating innovation for academia & industry. Uncover how we deliver measurable impact—faster. #innovation #startup #R&D
0
0
1
@CheloniaSwiss
Chelonia Applied Science
3 days
🧬 Extracellular Vesicles & Biomedicine – Join Us! 🧬 📅 12 Feb 2025 - 9am CET | 🏛 UniTuscia, Italy Discover how mEVs act as molecular carriers in #AVITHRAPID’s antiviral strategies! 🔬🦠 📡 Open event –
0
0
1
@CheloniaSwiss
Chelonia Applied Science
6 days
Don’t miss the #AICHEMIST Workshop (April 28 – May 2, 2025)! Dive into ML for chemical reaction prediction, synthesis planning, and explainable AI—all designed for both academia and industry. Register by March 28 👉
Tweet media one
0
0
0
@CheloniaSwiss
Chelonia Applied Science
7 days
RT @avithrapid: Researchers are racing to develop broad-spectrum antivirals to defend us from emerging threats. With AI-driven drug discove…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
11 days
RT @avithrapid: 🌟 Game changer in biotech! MIT’s #Boltz-1 is here: the first fully open-source AI rivaling #AlphaFold3. Democratizing #prot
0
2
0
@CheloniaSwiss
Chelonia Applied Science
11 days
RT @avithrapid: What if we could develop antiviral treatments faster and smarter? AVITHRAPID attempts to do just that. Curious how we’re ta…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
11 days
RT @avithrapid: 🌍 Are we ready for the next pandemic? HERA highlight the need for broad-spectrum antivirals to boost preparedness. ⚠ Lesson…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
29 days
🌟 Game changer in biotech! MIT’s Boltz-1 is here: the first fully open-source AI rivaling AlphaFold3. Democratizing protein modeling for faster drug discovery and biomedical breakthroughs. 💻 Access Boltz-1, collaborate, innovate via blog post
0
0
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @avithrapid: 🚨 Stay in the loop with AVITHRAPID Project! 🚨 📩 Subscribe to our newsletter for exclusive insights into infectious disease…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @avithrapid: Season’s Greetings from AVITHRAPID! 🎄Thank you for following us in the first project year! We are looking forward to keep y…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @fra_grisoni: Great news to conclude 2024! I couldn’t think of a better team than the ones and only @narf42 and @robpollice to work on t…
0
6
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @avithrapid: 🚨 AVITHRAPID publishes critical data for drug development against #dengue! #AVITHRAPID modeled proteins of all 4 DENV serot…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @avithrapid: 🚨 Stay in the loop with AVITHRAPID Project! 🚨 📩 Subscribe to our newsletter for exclusive insights into infectious disease…
0
1
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @AiChemist_DN: The article "Screening the ToxCast Chemical Libraries for Binding to Transthyretin" which provide…
0
5
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @AiChemist_DN: What was a busy week! After lecture and participation to PhD defense at Shenzhen Institute of Advanced Technology, I had…
0
2
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @Jie_William_Xia: Our modeling work with Dr. Igor Tetko @AiddOne , which focuses on Plasma Protein Binding (PPB), has been published in…
0
3
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @jablonkagroup: Does this work excite you? Are you a prospective PhD, postdoc, or technical assistant? Look no further! Thanks to a ge…
0
5
0
@CheloniaSwiss
Chelonia Applied Science
2 months
RT @AiChemist_DN: "Can Publishing Neural Networks Expose Confidential Training Data?" Fabian Krüger will dive into the details during the A…
0
3
0